HCP Stock Price Target and Analyst Ratings (NYSE:HCP)

Analyst Price Target for HCP

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

^$0.00

▼ -100.00% Downside Potential

This price target is based on 0 analysts offering 12 month price targets for HCP in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $29.77.

N/A

The current consensus among 0 contributing investment analysts is to n/a stock in HCP. This rating has held steady since October 2020, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
12 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

9/10/2019

0 strong buy ratings
9 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

12/9/2019

0 strong buy ratings
7 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

3/8/2020

0 strong buy ratings
7 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

6/6/2020

0 strong buy ratings
5 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

9/4/2020

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

12/3/2020

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

2/1/2021

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

3/3/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price	Details
10/8/2019	JPMorgan Chase & Co.	Upgrade	Neutral ➝ Overweight	$35.00 ➝ $38.00	Low	i Rating by Anthony Paolone at JPMorgan Chase & Co.
10/2/2019	Barclays	Boost Price Target	Overweight	$37.00 ➝ $39.00	Low	i
10/2/2019	KeyCorp	Boost Price Target	Overweight	$34.00 ➝ $37.00	Low	i
9/30/2019	Scotiabank	Set Price Target	Buy	$38.00	Medium	i Rating by Nicholas Yulico at Scotiabank
9/17/2019	Morgan Stanley	Boost Price Target	Equal Weight	$32.00 ➝ $35.00	High	i Rating by Vikram Malhorta at Morgan Stanley
9/10/2019	JPMorgan Chase & Co.	Boost Price Target	Neutral	$32.00 ➝ $35.00	High	i
9/10/2019	Argus	Upgrade	Hold ➝ Buy		High	i
9/3/2019	Barclays	Initiated Coverage	Overweight	$37.00	High	i
9/3/2019	Stifel Nicolaus	Boost Price Target	Buy	$34.00 ➝ $37.00	High	i
8/1/2019	Stifel Nicolaus	Boost Price Target	Buy	$32.00 ➝ $34.00	Medium	i
7/1/2019	KeyCorp	Boost Price Target	Overweight	$32.00 ➝ $34.00	Medium	i
6/13/2019	Raymond James	Upgrade	Market Perform ➝ Outperform	$35.00	Medium	i
3/28/2019	Morgan Stanley	Set Price Target	Hold	$32.00	Medium	i Rating by Vikram Malhorta at Morgan Stanley
2/13/2019	BMO Capital Markets	Reiterated Rating	Buy	$33.00	Low	i
1/9/2019	BMO Capital Markets	Upgrade	Market Perform ➝ Outperform	$30.00 ➝ $33.00	Low	i
1/7/2019	Robert W. Baird	Upgrade	Neutral ➝ Outperform		Medium	i
12/10/2018	Scotiabank	Initiated Coverage	Outperform	$32.00	Medium	i
11/2/2018	Royal Bank of Canada	Upgrade	Sector Perform ➝ Outperform		Medium	i
11/1/2018	Cantor Fitzgerald	Boost Price Target	Overweight ➝ Overweight	$29.00 ➝ $30.00	Medium	i Rating by J. France at Cantor Fitzgerald
10/31/2018	BMO Capital Markets	Reiterated Rating	Hold	$27.00	High	i
10/5/2018	JPMorgan Chase & Co.	Downgrade	Overweight ➝ Neutral		Low	i
9/27/2018	Cantor Fitzgerald	Upgrade	Neutral ➝ Overweight	$28.00 ➝ $29.00	High	i Rating by J. France at Cantor Fitzgerald
9/17/2018	Bank of America	Boost Price Target	Buy	$27.50 ➝ $28.00	Medium	i
8/16/2018	Morgan Stanley	Boost Price Target	Equal Weight ➝ Equal Weight	$23.50 ➝ $25.00	Low	i
8/13/2018	Mizuho	Reiterated Rating	Buy	$29.00	Low	i Rating by Richard Anderson at Mizuho
8/9/2018	Robert W. Baird	Boost Price Target	Neutral ➝ Neutral	$24.00 ➝ $26.00	Low	i Rating by Drew Babin at Robert W. Baird
8/7/2018	Cantor Fitzgerald	Initiated Coverage	Neutral	$28.00	Low	i
8/3/2018	Stifel Nicolaus	Set Price Target	Buy ➝ Buy	$27.00 ➝ $28.00	Low	i Rating by Chad Vanacore at Stifel Nicolaus
7/24/2018	Capital One Financial	Initiated Coverage	Equal Weight	$27.50	Low	i
7/23/2018	Capital One Financial	Reiterated Rating	Equal Weight		Low	i Rating by D. Bernstein at Capital One Financial Co.
6/14/2018	Morgan Stanley	Lower Price Target	Equal Weight ➝ Equal Weight	$28.00 ➝ $23.50	Low	i
6/1/2018	Raymond James	Reiterated Rating	Market Perform		Low	i Rating by Jonathan Hughes at Raymond James
6/1/2018	Evercore ISI	Downgrade	In-Line ➝ Underperform		Low	i
5/21/2018	Evercore ISI	Downgrade	In-Line ➝ Underperform	$23.02 ➝ $24.00	Low	i
5/21/2018	Raymond James	Downgrade	Outperform ➝ Market Perform		Low	i Rating by Jonathan Hughes at Raymond James
5/3/2018	BMO Capital Markets	Reiterated Rating	Hold	$25.00	Low	i Rating by John Kim at BMO Capital Markets
3/20/2018	Wells Fargo & Company	Lower Price Target	Market Perform ➝ Market Perform	$31.00 ➝ $27.00	Low	i
3/8/2018	Bank of America	Upgrade	Neutral ➝ Buy	$22.63 ➝ $25.00	Low	i Rating by Juan C. Sanabria at Bank of America Co.
2/23/2018	Royal Bank of Canada	Reiterated Rating	Hold	$27.00	Low	i
2/21/2018	UBS Group	Reiterated Rating	Sell ➝ Sell	$25.00 ➝ $21.00	Medium	i Rating by Nicholas Yulico at UBS Group AG
2/15/2018	Robert W. Baird	Set Price Target	Hold	$24.00	Low	i Rating by Drew Babin at Robert W. Baird
2/15/2018	Mizuho	Set Price Target	Buy	$26.00	Low	i Rating by Richard Anderson at Mizuho
2/14/2018	Stifel Nicolaus	Reiterated Rating	Buy ➝ Buy	$29.00 ➝ $27.00	High	i Rating by Chad Vanacore at Stifel Nicolaus
2/13/2018	Jefferies Financial Group	Reiterated Rating	Hold	$26.00	Medium	i
2/13/2018	BMO Capital Markets	Set Price Target	Hold	$25.00	Medium	i Rating by John Kim at BMO Capital Markets
1/15/2018	BMO Capital Markets	Set Price Target	Hold	$25.00	Low	i Rating by John Kim at BMO Capital Markets
1/5/2018	Robert W. Baird	Lower Price Target	Neutral ➝ Neutral	$29.00 ➝ $26.00	Medium	i
12/15/2017	JPMorgan Chase & Co.	Upgrade	Neutral ➝ Overweight	$29.00	Medium	i
12/14/2017	Morgan Stanley	Reiterated Rating	Equal Weight	$29.00	Low	i
12/5/2017	Stifel Nicolaus	Upgrade	Hold ➝ Buy	$29.00	Low	i
11/7/2017	Stifel Nicolaus	Lower Price Target	Hold ➝ Hold	$30.00 ➝ $29.00	N/A	i
11/2/2017	Mizuho	Upgrade	Neutral ➝ Buy	$32.00	N/A	i
10/18/2017	BMO Capital Markets	Reiterated Rating	Hold	$28.00	N/A	i
10/17/2017	KeyCorp	Reiterated Rating	Hold		N/A	i
10/4/2017	Stifel Nicolaus	Reiterated Rating	Hold	$30.00	Low	i
10/2/2017	UBS Group	Downgrade	Neutral ➝ Sell	$30.00 ➝ $25.00	High	i
9/25/2017	Morgan Stanley	Lower Price Target	Equal Weight	$31.00 ➝ $29.00	Low	i
9/22/2017	Bank of America	Downgrade	Buy ➝ Neutral	$33.00 ➝ $31.00	High	i Rating by Juan C. Sanabria at Bank of America Co.
9/17/2017	KeyCorp	Reiterated Rating	Hold		Low	i
9/6/2017	BMO Capital Markets	Reiterated Rating	Hold	$32.00	Low	i
8/22/2017	Stifel Nicolaus	Reiterated Rating	Hold	$30.00	Medium	i
7/25/2017	Jefferies Financial Group	Reiterated Rating	Hold	$33.00	Low	i
7/24/2017	The Goldman Sachs Group	Downgrade	Buy ➝ Neutral	$35.00 ➝ $32.00	Medium	i
7/14/2017	Stifel Nicolaus	Reiterated Rating	Hold	$31.00	Medium	i
7/5/2017	Royal Bank of Canada	Reiterated Rating	Hold	$31.00	High	i
6/28/2017	Mizuho	Reiterated Rating	Neutral		Low	i
6/14/2017	Raymond James	Upgrade	Underperform ➝ Outperform	$35.00	Low	i
6/14/2017	UBS Group	Upgrade	Underperform ➝ Outperform		N/A	i
5/12/2017	Jefferies Financial Group	Reiterated Rating	Hold	$32.00	High	i
4/24/2017	Evercore ISI	Downgrade	In-Line ➝ Underperform		Medium	i
4/21/2017	Mitsubishi UFJ Financial Group	Initiated Coverage	Hold	$32.00	Low	i Rating by Karin Ford at Mitsubishi UFJ Financial Group
4/11/2017	Mizuho	Downgrade	Buy ➝ Neutral	$34.00 ➝ $32.00	Low	i Rating by Richard Anderson at Mizuho
4/3/2017	Bank of America	Upgrade	Neutral ➝ Buy	$33.25 ➝ $35.00	Low	i
3/27/2017	Evercore ISI	Upgrade	Underperform ➝ In-Line		Low	i
3/20/2017	Morgan Stanley	Upgrade	Underweight ➝ Equal Weight	$31.00	Low	i
3/10/2017	Robert W. Baird	Initiated Coverage	Neutral ➝ Neutral	$32.00	Low	i
3/3/2017	Evercore ISI	Downgrade	Hold ➝ Underperform		N/A	i
2/14/2017	BMO Capital Markets	Reiterated Rating	Hold	$30.00	N/A	i
2/14/2017	Barclays	Boost Price Target	Equal Weight	$32.00 ➝ $33.00	N/A	i
1/25/2017	The Goldman Sachs Group	Upgrade	Neutral ➝ Buy	$29.00 ➝ $35.00	N/A	i
1/5/2017	Barclays	Reiterated Rating	Equal Weight	$32.00	N/A	i
1/3/2017	Royal Bank of Canada	Set Price Target	Hold	$30.00	N/A	i Rating by Michael A. Carroll at Royal Bank of Canada
12/23/2016	Mizuho	Reiterated Rating	Buy		N/A	i Rating by Richard Anderson at Mizuho
12/13/2016	BMO Capital Markets	Upgrade	Underperform ➝ Market Perform	$29.00 ➝ $30.00	N/A	i Rating by John Kim at BMO Capital Markets
11/21/2016	Mizuho	Upgrade	Neutral ➝ Buy	$31.00 ➝ $32.00	N/A	i Rating by Richard Anderson at Mizuho
11/4/2016	Royal Bank of Canada	Upgrade	Underperform ➝ Sector Perform	$35.00 ➝ $30.00	N/A	i
11/2/2016	Stifel Nicolaus	Upgrade	Sell ➝ Hold	$33.00 ➝ $31.00	N/A	i
11/2/2016	Mizuho	Lower Price Target	Neutral	$37.00 ➝ $31.00	N/A	i Rating by Richard Anderson at Mizuho
11/1/2016	BTIG Research	Reiterated Rating	Neutral		N/A	i
11/1/2016	BMO Capital Markets	Reiterated Rating	Sell	$33.00	N/A	i Rating by John Kim at BMO Capital Markets
10/4/2016	Bank of America	Upgrade	Underperform ➝ Neutral	$38.50	N/A	i
9/18/2016	Argus	Reiterated Rating	Hold		N/A	i Rating by jacob kilstein at Argus
9/4/2016	Wells Fargo & Company	Reiterated Rating	Hold		N/A	i
8/25/2016	BTIG Research	Initiated Coverage	Neutral		N/A	i
8/24/2016	Citigroup	Boost Price Target	Neutral	$34.00 ➝ $38.00	N/A	i
8/23/2016	UBS Group	Boost Price Target	Neutral	$35.00 ➝ $38.00	N/A	i Rating by Nicholas Yulico at UBS Group AG
8/10/2016	Mizuho	Boost Price Target	Neutral	$32.00 ➝ $37.00	N/A	i Rating by Richard Anderson at Mizuho
7/26/2016	Raymond James	Initiated Coverage	Underperform		N/A	i
7/12/2016	Mizuho	Reiterated Rating	Hold	$32.00	N/A	i Rating by Richard Anderson at Mizuho
7/8/2016	The Goldman Sachs Group	Upgrade	Sell ➝ Neutral	$26.00 ➝ $36.00	N/A	i Rating by Andrew Rosivach at The Goldman Sachs Group, Inc.
7/6/2016	Jefferies Financial Group	Reiterated Rating	Hold ➝ Neutral		N/A	i Rating by Omotayo Okusanya at Jefferies Financial Group Inc.
6/22/2016	Morgan Stanley	Downgrade	Equal Weight ➝ Underweight	$32.00	N/A	i
6/20/2016	BMO Capital Markets	Reiterated Rating	Sell		N/A	i Rating by John Kim at BMO Capital Markets
6/15/2016	Argus	Reiterated Rating	Hold		N/A	i Rating by Jacob Kilstein at Argus
6/1/2016	Barclays	Downgrade	Equal Weight ➝ Underweight	$40.00 ➝ $37.00	N/A	i Rating by Joshua Raskin at Barclays PLC
5/16/2016	Citigroup	Boost Price Target	Neutral	$31.00 ➝ $34.00	N/A	i
5/10/2016	BMO Capital Markets	Reiterated Rating	Sell		N/A	i
5/10/2016	Jefferies Financial Group	Upgrade	Underperform ➝ Hold	$25.00 ➝ $32.00	N/A	i
4/7/2016	Jefferies Financial Group	Boost Price Target		$25.00	N/A	i
3/28/2016	The Goldman Sachs Group	Reiterated Rating	Sell		N/A	i
3/21/2016	Evercore ISI	Boost Price Target		$32.00	N/A	i
3/16/2016	JPMorgan Chase & Co.	Reiterated Rating	Hold		N/A	i Rating by Michael Mueller at JPMorgan Chase & Co.
3/16/2016	UBS Group	Downgrade	Buy ➝ Neutral	$31.00	N/A	i
3/15/2016	JPMorgan Chase & Co.	Lower Price Target	Neutral	$39.00 ➝ $35.00	N/A	i
3/10/2016	Barclays	Lower Price Target	Underweight	$37.00 ➝ $33.00	N/A	i
3/3/2016	Mizuho	Boost Price Target	Neutral	$26.00 ➝ $32.00	N/A	i Rating by Richard Anderson at Mizuho

(Data available from 3/3/2016 forward)

HCP, Inc. is a fully integrated real estate investment trust (REIT) that invests in real estate serving the healthcare industry in the United States. HCP owns a large-scale portfolio primarily diversified across life science, medical office and senior housing. Recognized as a global leader in sustainability, HCP has been a publicly-traded company since 1985 and was the first healthcare REIT selected to the S&P 500 index.

Today's Range

Now: $29.77

$29.09

$30.00

50 Day Range

MA: $30.54

$28.42

$35.78

52 Week Range

Now: $29.77

$26.58

$37.93

Volume

5,302,189 shs

Average Volume

3,008,769 shs

Market Capitalization

$14.62 billion

P/E Ratio

16.36

Dividend Yield

4.14%

Beta

0.22

Frequently Asked Questions

What sell-side analysts currently cover shares of HCP?

The following sell-side analysts have issued stock ratings on HCP in the last year:
View the latest analyst ratings for HCP.

What is the current price target for HCP?

0 Wall Street analysts have set twelve-month price targets for HCP in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for HCP in the next year.
View the latest price targets for HCP.

What is the current consensus analyst rating for HCP?

HCP currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for HCP.

What other companies compete with HCP?

Other companies that are similar to HCP include American Tower, Public Storage, Welltower, Weyerhaeuser, Ventas, Extra Space Storage, Medical Properties Trust, Omega Healthcare Investors, CubeSmart, Life Storage, Rayonier, Ryman Hospitality Properties, Healthcare Realty Trust, Sabra Health Care REIT and EPR Properties.

How do I contact HCP's investor relations team?

HCP's physical mailing address is 1920 MAIN STREET SUITE 1200, IRVINE CA, 92614. The real estate investment trust's listed phone number is 949-407-0700 and its investor relations email address is [email protected] The official website for HCP is www.hcpi.com.

NYSE:HCP - HCP Stock Price Target and Predictions

Analyst Price Target for HCP

Past Monthly Recommendations

Latest Recommendations

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of HCP?

What is the current price target for HCP?

What is the current consensus analyst rating for HCP?

What other companies compete with HCP?

How do I contact HCP's investor relations team?